Determination of oxidative stress status and concentration of TGF-β1 in the blood and saliva of osteoporotic subjects

Annals of the New York Academy of Sciences

Volumn 1091, Issue , 2006, Pages 142-150

  Yousefzadeh, Gholamreza ^a   Larijani, Bagher ^a   Mohammadirad, Azadeh ^b   Heshmat, Ramin ^a   Dehghan, Gholamreza ^b   Rahimi, Roja ^b   Abdollahi, Mohammad ^b  

^a TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Blood; Osteoporosis; Oxidative stress; Saliva; TGF

Indexed keywords

ANTIOXIDANT; THIOBARBITURIC ACID REACTIVE SUBSTANCE; TRANSFORMING GROWTH FACTOR BETA1; SALIVA PROTEIN;

ADULT; BLOOD SAMPLING; BONE DENSITY; CLINICAL ARTICLE; CONFERENCE PAPER; CONTROLLED STUDY; FEMALE; HUMAN; LIPID PEROXIDATION; OSTEOPOROSIS; OXIDATIVE STRESS; SALIVA LEVEL; ARTICLE; BLOOD; METABOLISM; MIDDLE AGED; PHYSIOLOGY; SALIVA;

FEMALE; HUMANS; MIDDLE AGED; OSTEOPOROSIS; OXIDATIVE STRESS; SALIVA; SALIVARY PROTEINS; TRANSFORMING GROWTH FACTOR BETA1;

EID: 33947600578     PISSN: 00778923     EISSN: 17496632     Source Type: Book Series    
DOI: 10.1196/annals.1378.062     Document Type: Conference Paper

References (41)

1. 1991. Consensus development conference: prophylaxis and treatment of osteoporosis. Am J. Med. 90: 107-110.
2. MONOLOGAS, S.C. & R.L. JILKA. 1995. Bone marrow, cytokines and remodeling: emerging insights into the pathophysiology of osteoporosis. N. Engl. J. Med. 322: 305-311.
3. BOYLE, W.J., W.S. SIMONET & D.L. LACEY. 2003. Osteoclast differentiation and activation. Nature 423: 337-342.
4. MONOLAGAS, S.C. 2000. Birth and death of bone cells. Basic regulatory mechanisms and implications for the pathogenesis and treatment of osteoporosis. Endocr. Rev. 21: 115-117.
5. AFSHARI, M., B. LARIJANI, A. REZAIE, et al. 2004. Ineffectiveness of allopurinol in reduction of oxidative stress in diabetic patients; a randomized, double-blind placebo-controlled clinical trial. Biomed. Pharmacother. 58: 546-550.
6. JAHANSHAHI, G., V. MOTAVASEL, A. REZAIE, et al. 2004. Alterations in antioxidant power and levels of epidermal growth factor and nitric oxide in saliva of patients with inflammatory bowel diseases. Dig. Dis. Sci. 49: 1752-1757.
7. ASTANEIE, F., M. AFSHARI, A. MOJTAHEDI, et al. 2005. Total antioxidant capacity and levels of epidermal growth factor and nitric oxide in blood and saliva of insulin-dependent diabetic patients. Arch. Med. Res. 36: 376-381.
8. RADFAR, M., B. LARIJANI, M. HADJIBABAIE, et al. 2005. Effects of pentoxifylline on oxidative stress and levels of EGF andNOin blood of diabetic type-2 patients; a randomized, double-blind placebo-controlled clinical trial. Biomed. Pharmacother. 59: 302-306.
9. RAHIMI, R., S. NIKFAR, B. LARIJANI & M. ABDOLLAHI. 2005. A review on the role of antioxidants in the management of diabetes and its complications. Biomed. Pharmacother. 59: 365-373.
10. MASHAYEKHI, F., F. AGHAHOSEINI, A. REZAIE, et al. 2005. Alteration of cyclic nucleotides levels and oxidative stress in saliva of human subjects with periodontitis. J. Contemp. Dent. Pract. 4: 046-053.
11. ABDOLLAHI, M., B. LARIJANI, R. RAHIMI & P. SALARI. 2005. Role of oxidative stress in osteoporosis. Therapy 2: 787-796.
12. ABDOLLAHI, M., A. RANJBAR, S. SHADNIA, et al. 2004. Pesticides and oxidative stress: a review. Med. Sci. Monit. 10: RA144-RA147.
13. FINKEL, T. & N.J. HOLBROOK. 2000. Oxidants, oxidative stress and biology of aging. Nature 408: 239-247.
14. YALIN, S., S. BAGIS, G. POLAT, et al. 2005. Is there a role of free oxygen radicals in primary male osteoporosis? Clin. Exp. Rheumatol. 23: 689-692.
15. MAGGIO, D., M. BARABANI, M. PIERANDREI, et al. 2003. Marked decrease in plasma antioxidants in aged osteoporotic women: results of a cross-sectional study. J. Clin. Endocrinol. Metab. 88: 1523-1527.
16. BASU, S., K. MICHAELSSON, H. OLOFSSON, et al. 2001. Association between oxidative stress and bone mineral density. Biochem. Biophys. Res. Commun. 288: 275-279.
17. GRAINGER, D.J., J. PERCIVAL, M. CHIANO & T.D. SPECTOR. 1999. The role of serum TGF-beta isoforms as potential markers of osteoporosis. Osteoporos. Int. 9: 398-404.
18. MOHAN, S. & D.J. BAYLINK. 1991. Bone growth factors. Clin. Orthop. 263: 30-48.
19. CENTRELLA, M., S. CASINIGHINO, R. IGNOTZ & T.L. MCCARTHY. 1992. Multiple regulatory effects by TGF-β on type-I collagen levels in osteoblast-enriched cultures from fetal rat bone. Endocrinology 131: 2863-2872.
20. HUGHES, D.E., A.H. DAI, J.C. TIFFEE, et al. 1996. Oestrogen promotes apoptosis of murine osteoclasts mediated by TGF-β. Nat. Med. 2: 1132-1137.
21. BEAUDREUIL, J., G. MBALAVIELE, M. COHENSOLAL, et al. 1995. Short-term local injections of TGF-β1 decrease oviarectomy-stimulated osteoclastic resorption in vivo in rats. J. Bone Miner. Res. 10: 971-977.
22. MASSAGUE, J. 1990. The transforming growth factor β family. Annu. Rev. Cell. Biol. 6: 597-641.
23. GRAINGER, D.J., D.E. MOSEDALE, J.C. METCALFE, et al. 1995. Active and acidactivatable TGF-β in human sera, platelets and plasma. Clin. Chim. Acta 235: 11-31.
24. DANIELPOUR, D., K.Y. KIM, L.L. DART, et al. 1990. Evidence for differential regulation of TGF-β1 and TGF-β2 expression in vivo by sandwich enzyme-linked immunosorbent assays. Ann. N.Y. Acad. Sci. 593: 300-302.
25. NICOLAS, V., A. PREWETT, P. BETTICA, et al. 1994. Age-related decreases in insulinlike growth factor-I and transforming growth factor-beta in femoral cortical bone from both men and women: implications for bone loss with aging. J. Clin. Endocrinol. Metab. 78: 1011-1016.
26. GEORGESCU, C., T. SECK, I. DIEL, et al. 2004. Bone matrix insulin-like growth factor (IGF)-I, IGF-II and transforming growth factor (TGF)-beta1 levels in men and postmenopausal women with osteoporosis: lack of association with circulating growth factors and bone mineral density. Rev. Med. Chir. Soc. Med. Nat. Iasi 108: 281-286.
27. BARAN, D.T., K.G. FAULKNER, H.K. GENANT, et al. 1997. Diagnosis and management of osteoporosis: guidelines for the utilization of bone densitometry. Calcif. Tissue Int. 61: 433-440.
28. ABDOLLAHI, M. & M. RADFAR. 2003. A review of drug-induced oral reactions. J. Contemp. Dent. Pract. 4: 10-31.
29. BENSI, I.F. & S. STRAINS. 1999. Ferric reducing antioxidant assay. Methods Enzymol. 292: 15-27.
30. SATHO, K. 1978. Serum lipid peroxidation in cerebrovascular disorders determined by a new colorimetric method. Clin. Chem. Acta 90: 37-43.
31. KIM, S.J., D. ROMEO, Y.D. YOO & K. PARK. 1994. Transforming growth factor-beta: expression in normal and pathological conditions [review]. Horm. Res. 42: 5-8.
32. BAX, B.E., A.S.T.M. ALAM, B. BANERJI, et al. 1992. Stimulation of osteoblastic bone resorption by hydrogen peroxide (H2O2). Biochem. Biophys. Res. Commun. 183: 1153-1158.
33. SUDA, N., I. MORITA, T. KURODA & S. MUROTA. 1997. Participation of oxidative stress in the process of osteoclast differentiation. Biochim. Biophys. Acta 1157: 318-323.
34. MODY, M., F. PARHAMI, T.A. SARAFIAN & L.L. DEMER. 2001. Oxidative stress modulates osteoblastic differentiation of vascular and bone cells. Free Radical Bio. Med. 31: 509-519.
35. BRAYBOY, J.R., X.W. CHEN, Y.S. LEE & J.J.B. ANDERSON. 2001. The protective effects of Ginkgo biloba extract (EGb 761) against free radical damage to osteoblast-like bone cells (MC3T3-E1) and the proliferative effects of EGb 761 on these cells. Nutr. Res. 21: 1275-1285.
36. SUZUKI, H., M. HAYAKAWA, K. KOBAYASHI, et al. 1997. H2O2-derived free radicals treated fibrinectin substratum reduces the bone nodule formation of rat calvarial osteoblast. Mech. Ageing Dev. 98: 113-125.
37. DARDEN, A.G., W.L. RIES, W.C. WOLF, et al. 1996. Osteoclastic superoxide production and bone resorption: stimulation and inhibition by modulators of NADPH oxidase. J. Bone Miner. Res. 11: 671-675.
38. RIES, W.L., L.L. KEY & R. RODRIGUIZ. 1992. Nitroblue tetrazolium reduction and bone resorption by osteoclasts in vitro inhibited by a manganese-based superoxide dismutase mimic. J. Bone Miner. Res. 7: 931-939.
39. STEINBECK, M.J., W.H. APPEL, A.J. VERHOEVEN & M.J. KARNOVSKY. 1994. NADPH-oxidase expression and in situ production of superoxide byosteoclasts actively resorbing bone. J. Cell. Biol. 26: 765-772.
40. PENCKOFER, S., D. SCHWERTZ & K. FLERCZAK. 2002. Oxidative stress and cardiovascular disease in type 2 diabetes: the role of antioxidants and pro-oxidants. J. Cardiovasc. Nurs. 16: 68-85.
41. LEE, Y.S., X. CHEN & J.J.B. ANDERSON. 2001. Physiological concentrations of genistein stimulate the proliferation and protect against free radical induced oxidative damage of MC3T3-E1 osteoblast-like cells. Nutr. Res. 21: 1287-1298.